We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -4.42 | -0.57% | 776.68 | 781.60 | 768.25 | 774.57 | 1,550,246 | 19:33:02 |
From May 2021 to May 2024
By Colin Kellaher
Innovent Biologics Inc. and Eli Lilly & Co. on Tuesday said the U.S. Food and Drug Administration accepted for review a biologics license application for sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line treatment of nonsquamous non-small cell lung cancer.
The companies said the FDA didn't identify any potential review issues and isn't currently planning to hold an advisory committee meeting to discuss the application, adding that the agency set a target action date in March 2022.
Indianapolis drugmaker Eli Lilly and Innovent, a Suzhou, China, pharmaceutical company, have been collaborating since March 2015. The filing marks the first U.S. regulatory submission of sintilimab, which the companies jointly developed and is marketed as Tyvyt in China.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 18, 2021 06:42 ET (10:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
